Igenica Inc

Biopharmaceutical firm Igenica Inc nabs additional $14M in Series C extension funding

Igenica Inc, the biopharmaceutical firm dedicated to developing antibodies and antibody-drug conjugates to treat the Big C, obtained $14 million in its Series C extension round.

Read Full Article

Subscribe to VCpost newsletter

Sign up for our Deals of the Day newsletter.
We will not spam you!

Real Time Analytics